Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Breast Cancer Clinical Trial

Official title:

A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03596073
• Other study ID #: 18-040
• Status: Terminated
• Phase: Phase 1
• Start date: November 7, 2018
• Est. completion date: August 31, 2020

Study information

• Verified date: March 2024
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is studying a topical ointment called calcipotriene to see if it can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal

Description:

The investigators are doing this research study to find out how topical calcipotriene ointment affect people who have breast cancer, and what impact that may have on those who are at risk of developing breast cancer in the future. The investigators hope that what they learn will lead to the development of a new medication for the treatment and prevention of breast cancer.

Abnormal breast lesions can be benign, premalignant or malignant. These lesions are being targeted by the topical calcipotriene ointment. The investigators aim to determine whether this topical treatment can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal.

Calcipotriene ointment is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis, but calcipotriene ointment is not approved by the FDA to treat breast cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 43
• Est. completion date: August 31, 2020
• Est. primary completion date: August 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Participants must have histologically confirmed benign, premalignant or early malignant breast lesions on core biopsy that will proceed directly to surgical removal without any intervening neoadjuvant chemotherapy.

• Patients diagnosed with benign breast lesions (papilloma and sclerosing lesion), flat epithelial atypia, atypical ductal hyperplasia, lobular carcinoma in situ (Tis N0 M0; stage 0), ductal carcinoma in situ (Tis N0 M0; stage 0), primary invasive ductal and lobular carcinoma (T1or2 N0or1 M0; stage I-II), who will directly receive surgery and no neoadjuvant chemotherapy.

• Patients with hormone receptor positive, Her2 positive and triple negative cancers will be eligible.

• Patients with multicentric and multifocal tumors will be eligible.

• Age 45 years. To avoid the impact of menstrual cycles-associated alterations in the immune environment of the breast, the age is limited to post-menopausal women.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Participants scheduled to undergo neoadjuvant therapy for breast cancer.

• Participants with metastatic breast cancer.

• Participants with history of breast cancer in the past 5 years.

• Participants with immunosuppression (e.g., organ transplant recipients and patients with autoimmune diseases requiring immunosuppressive medications including >5mg daily prednisone, methotrexate, cyclosporine, azothioprine, tacrolimus and TNFa blocking agents)

• Participants with the history of hypercalcemia or clinical evidence of vitamin D toxicity.

• Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

• Participants who are receiving any other investigational agents.

• Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to topical calcipotriene ointment.

• Pregnant women are excluded from this study because topical calcipotriol ointment is a category C agent and its impact on developing fetus is unknown. In addition, premenopausal women are excluded from this study due to the impact of menstrual cycles on immune environment of the breast.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Topical Calcipotriene Ointment
Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.

Other:
• Topical Vaseline
Placebo

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The changes in the magnitude of CD3+ T cell infiltration in tumor microenvironment	The change in the number of CD3+ T cells per high power microscope field in tumor microenvironment from the time of initial needle core biopsy to surgical excision.	3 Weeks
Secondary	The comprehensive changes in tumor immune microenvironment		3 Weeks
Secondary	The changes in tumor immune microenvironment in patients with neoplastic tumors versus benign lesions		3 Weeks
Secondary	The changes in tumor immune microenvironment in patients with stage I-II, versus stage 0 tumors		3 Weeks
Secondary	The changes in tumor immune microenvironment in patients with hormone receptor and Her2 positive versus triple negative tumors		3 Weeks
Secondary	Serum Serum Thymic Stromal Lymphopoietin (TSLP) levels (picogram/milliliter) before and after topical calcipotriene treatment compared to Vaseline control group		3 Weeks
Secondary	Disease free survival	The duration of time measured from the start of treatment until the time of disease progression or death, whichever occurs first.	From the start of treatment up to 15 years
Secondary	Number of Participants with Treatment Related Adverse Events	Adverse events will be assessed using Common Terminology Criteria for Adverse Events (CTCAE v4).	From the start of treatment until 30 days after the end of treatment, up to 2 months